AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK

Mitsubishi Tanabe Pharma America, Inc. today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial evaluating the long-term safety

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein

Pharmatech Associates today announced a strategic alliance that brings PCM expertise and capabilities to the marketplace to tackle drug shortages and supply chain issues by providing drug sponsors and manufacturers a more effective means of making finished drug products

MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

Biocytogen Pharmaceuticals Co., Ltd. today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider

NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 an investigational treatment for myelofibrosis a rare and incurable blood cancer.

National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing